CLINICAL_TRIALS
trial_result
· 2020-02-10
Clinical Trial Update: Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer [Phase 2]
Summary
Phase 2 trial update of pembrolizumab plus paclitaxel in refractory small cell lung cancer has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Seoul National University Hospital | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-02-10